Victoza® (liraglutide) news archive
22 October 2009
New study results show that patients have higher treatment satisfaction with liraglutide compared to exenatide
30 September 2009
New data shows that patients with type 2 diabetes improve their blood sugar control when switched to Victoza® from Byetta®
23 September 2009
Update on timeline for formal feedback on liraglutide from the FDA
6 August 2009
Interim financial report for the period 1 January 2009 to 30 June 2009
3 July 2009
Novo Nordisk's Victoza® (liraglutide) receives marketing authorisation in Europe
9 June 2009
The Lancet publishes direct comparison study between liraglutide and exenatide
24 April 2009
Novo Nordisk receives positive opinion on Victoza® (liraglutide) from the European regulatory authorities
2 April 2009
Update on FDA Advisory Committee meeting on liraglutide for the treatment of type 2 diabetes
31 March 2009
Liraglutide briefing documents now available for the FDA Advisory Committee meeting on 2 April
29 January 2009
Financial statement for 2008
18 November 2008
FDA reschedules Advisory Committee meeting for liraglutide - no change of review timeline anticipated
17 October 2008 (LEAD™ 6)
New data from head-to-head phase 3 trial demonstrate that liraglutide is more effective than exenatide in treatment of type 2 diabetes
26 September 2008
Novo Nordisk provides update on corporate strategy at its Capital Markets Day
25 September 2008 (LEAD™ 3)
Data from one-year liraglutide phase 3 study published in The Lancet
8 September 2008
New data from a phase 3 study confirms clinical benefits of once-daily liraglutide in the management of type 2 diabetes
5 September 2008
FDA schedules Advisory Committee meeting for liraglutide
7 August 2008
Financial statement for the period 1 January 2008 to 30 June 2008
15 July 2008
Novo Nordisk files for regulatory approval of liraglutide in Japan
9 June 2008 (LEAD™ 3)
Clinical study shows liraglutide reduced blood sugar, weight and blood pressure in patients with type 2 diabetes
6 June 2008 (LEAD™ 6)
Clinical study shows liraglutide provides statistically significantly better blood glucose control than exenatide
23 May 2008
Novo Nordisk files for regulatory approval of liraglutide in both the US and Europe
11 December 2007 (LEAD™ 3)
Final phase 3 study confirms very favourable effect of liraglutide on blood glucose control and body weight
14 September 2007 (LEAD™ 4)
Phase 3 study confirms that liraglutide treatment leads to both glucose and weight reduction with a low risk of hypoglycaemic events
20 August 2007 (LEAD™ 1 and LEAD™ 2)
Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients
21 June 2007 (LEAD™ 5)
Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
